18-Methylaminocoronaridine
Identifiers | |
---|---|
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C22H29N3O2 |
Molar mass | 367.493 g·mol−1 |
3D model (JSmol) | |
| |
| |
(–)-18-Methylaminocoronaridine (18-MAC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist from the Albany Medical College and the chemist from the University of Vermont.[1][2]
See also[]
- 2-Methoxyethyl-18-methoxycoronaridinate
- 18-Methoxycoronaridine
- Coronaridine
- Ibogaine
- Noribogaine
- Voacangine
References[]
- ^ Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, et al. (June 2003). "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medicinal Chemistry. 46 (13): 2716–30. doi:10.1021/jm020562o. PMID 12801235.
- ^ Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.
Categories:
- Drug rehabilitation
- Iboga
- Nicotinic antagonists